ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 762

M10, a Caspase Cleavage Product of the Hepatocyte Growth Factor Receptor, Downregulates Bone Morphogenetic Protein-9-Induced Smad1/5/8 Phosphorylation and Collagen Production in Human Lung Fibroblasts

Atsushi Noguchi, Ilia Atanelishvili, Tanjina Akter, Richard M. Silver and Galina S. Bogatkevich, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Collagen, fibroblasts and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: We recently identified M10, a caspase cleavage product of the hepatocyte growth factor receptor, as an anti-fibrotic peptide that interacts with Smad2 and inhibits TGFβ-induced Smad2 phosphorylation and collagen production in human lung fibroblasts [1]. While Smad2/3 signaling pathway is mainly activated by TGFβ1 through type I receptor activin receptor-like kinase (ALK) 5, Smad1/5 signaling pathway is mainly activated by bone morphogenetic proteins (BMPs), which are other members of TGFβ superfamily, through ALK1/2/3/6 receptors. Recently, BMP9 has been identified as a pro-fibrotic ligand in mouse embryo fibroblasts [2]. In SSc fibroblasts, ALK1/Smad1/5 pathway is suggested to play a pivotal role in the regulation of fibrosis [3]. The aims of this study are to investigate the role of BMP9 in SSc lung fibroblasts and to examine the additional anti-fibrotic mechanisms of M10.

Methods: Fibroblasts were derived from lung tissues obtained at autopsy from SSc patients and from age- race-, and sex-matched normal subjects. MRC5 human fetal lung fibroblasts were purchased from Sigma. Potential peptide-protein interactions were modeled in-silico using PepSite [4]. Smad phosphorylation, type I collagen, and smooth muscle α-actin (α-SMA) expression were determined by immunoblotting and RT-PCR.

Results: Using a computational modulation approach available from PepSite, we found a statistically significant (p < 0.0001) potential interaction of M10 with the BMP9/ALK1/activin receptor type II B (ActRIIB) complex. The most probable binding sites are located at β-turn motifs in BMP9. We demonstrate that when recombinant BMP9 is added to the medium, phosphorylation of Smad1/5/8 is rapidly induced in MRC5 cells and SSc lung fibroblasts in a dose-dependent manner. The expression of type I collagen is upregulated after 48 hours treatment with BMP9 in MRC5 cells and SSc lung fibroblasts as well as normal lung fibroblasts. The expression of α-SMA is increased in normal lung fibroblasts in a dose dependent manner. Intriguingly, the anti-fibrotic peptide M10 significantly downregulated BMP9-induced type I collagen expression and α-SMA expression as well as Smad1/5/8 phosphorylation in lung fibroblasts.

Conclusion: We demonstrate that BMP9 shows pro-fibrotic effects in human fetal lung fibroblasts and in adult lung fibroblasts obtained from SSc patients and matched normal subjects. M10 peptide has a potential to bind to BMP9 and to inhibit BMP9-induced collagen production and epithelial-mesenchymal transition through the Smad1/5/8 signaling pathway.

References:

[1] Atanelishvili I, et al. Transl Res. 2016;170:99-111.

[2] Munoz-Felix JM, et al. Cell Signal. 2016;28:1252-61.

[3] Munoz-Felix JM, et al. Cytokine Growth Factor Rev. 2013;24:523-37.

[4] Trabuco LG, et al. Nucleic Acids Res. 2012;40:W423-7.


Disclosure: A. Noguchi, None; I. Atanelishvili, None; T. Akter, None; R. M. Silver, NIH/NIAMS P60 AR062755, 2,SC SmartState®, 2; G. S. Bogatkevich, NIH/NIAMS P60 AR062755, 2,Scleroderma Foundation, 2.

To cite this abstract in AMA style:

Noguchi A, Atanelishvili I, Akter T, Silver RM, Bogatkevich GS. M10, a Caspase Cleavage Product of the Hepatocyte Growth Factor Receptor, Downregulates Bone Morphogenetic Protein-9-Induced Smad1/5/8 Phosphorylation and Collagen Production in Human Lung Fibroblasts [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/m10-a-caspase-cleavage-product-of-the-hepatocyte-growth-factor-receptor-downregulates-bone-morphogenetic-protein-9-induced-smad158-phosphorylation-and-collagen-production-in-human-lung-fibroblasts/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/m10-a-caspase-cleavage-product-of-the-hepatocyte-growth-factor-receptor-downregulates-bone-morphogenetic-protein-9-induced-smad158-phosphorylation-and-collagen-production-in-human-lung-fibroblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology